Adriamycin and Radiation: Synergistic Cardiotoxicity

Comments1 January 1975Adriamycin and Radiation: Synergistic CardiotoxicityJOHN MERRILL, M.D., F. ANTHONY GRECO, M.D., HARVEY ZIMBLER, M.D., HARMAR D. BRERETON, M.D., JOHN D. LAMBERG, M.D., THOMAS C. POMEROY, M.D.JOHN MERRILL, M.D.Search for more papers by this author, F. ANTHONY GRECO, M.D.Search for more papers by this author, HARVEY ZIMBLER, M.D.Search for more papers by this author, HARMAR D. BRERETON, M.D.Search for more papers by this author, JOHN D. LAMBERG, M.D.Search for more papers by this author, THOMAS C. POMEROY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-82-1-122_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Severe cardiomyopathy with irreversible congestive heart failure from adriamycin is very rare if the dose is limited to below 500 to 550 mg/m2 body surface area (1, 2). We have seen two patients who developed severe cardiac failure after receiving less than 500 mg/m2 body surface area of adriamycin in conjunction with therapeutic radiation to the thoracic spine and lungs. This seems to be a variable in the development of adriamycin cardiotoxicity.CASE 1An 11-year-old girl with Ewing's sarcoma of the right ilium metastatic to the skull and thoracic spine has been treated since 1972 with...References1. LEFRAKPITHAROSENHEIM EJS: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973 CrossrefMedlineGoogle Scholar2. BLUMCARTER RS: Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259, 1974 LinkGoogle Scholar3. COHNSTEWARTFAJARDO KJL: Heart disease following radiation. Medicine (Baltimore) 46(3):281-298, 1967 CrossrefGoogle Scholar4. ROSENWOLLNERTAN GNC: Disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 33:384-393, 1974 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Radiation Oncology Branch Division of Cancer Biology and Diagnosis National Cancer Institute, NIH Bethesda, Maryland 20014 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDoxorubicin‐Induced Cardiomyopathy in ChildrenA recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicityCritical Illness as a Result of Anti-Neoplastic TherapyCardiocutaneous Fistula in a Delayed Iathrogenic Ventricular Perforation of the HeartAnthracycline cardiotoxicityRadiation-associated cardiovascular diseaseStage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future studyCardiotoxicity of Cancer TherapyRadiation following chemotherapy for mediastinal Hodgkin's disease: the outcome of various doses for bulky tumorsCorazón y neoplasiasLONG-TERM SURVIVORS OF CHILDHOOD CANCERDirectional Coronary Atherectomy for the Diagnosis and Treatment of Radiation-Induced Coronary Artery StenosisDexrazoxane in the Prevention of Doxorubicin-Induced CardiotoxicityPulmonary complications of bone marrow transplantationDrugs ten years later: EpirubicinRadiation-induced coronary artery diseaseCardiovascular sequelae of therapeutic thoracic radiationLong-term cardiac sequelae after treatment of malignant tumors with radiotherapy or cytostatics in childhoodEchocardiography Findings in Children Treated for Malignancy with Chemotherapy Including AdriamycinPrevention of Acute Pulmonary Edema after Bone Marrow TransplantationPreoperative Evaluation of the Oncology PatientCase 27-1986Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low-dose administrationAdriamycin and Epirubicin Treatment Monitored by Radionuclide Ejection Fraction during Therapy and Follow-UpPossible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin CRadiation-induced heart disease: An updateRadionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicityFunktion des Perikards für die Pumpleistung des Herzens unter physiologischen und pathologischen BedingungenThoracic Radiotherapy ChangesMuscular pseudotumor of the breast following doxorubicin and radiation therapy for oat cell carcinoma of the lungPreliminary trial of combination therapy with adriamycin and radiation in sarcomas and other malignant tumorsDoxorubicin cardiotoxicityAdjuvant Treatment of OsteosarcomaTime dependent effects of adriamycin and x-ray therapy on wound healing in the ratEvaluation of the significance of prognostic factors in stage III Hodgkin's disease treated with MOPP and radiotherapyRisk Factors for Doxorubicin-lnduced Congestive Heart FailureDANIEL D. VON HOFF, M.D., MAXWELL W. LAYARD, Ph.D., PETER BASA, B.S., HUGH L. DAVIS Jr., M.D., ANN L. VON HOFF, M.A., MARCEL ROZENCWEIG, M.D., FRANCO M. MUGGIA, M.D.Anthracycline cardiomyopathy in childrenReport of two casesThe central nervous system in childhood leukemia.III. mineralizing microangiopathy and dystrophic calcificationAn acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung: a southwest oncology group studySYSTOLIC TIME INTERVAL TO PREDICT DOXORUBICIN CARDIOTOXICITYRADIONUCLEOTIDE EJECTION FRACTION AND PREDICTION OF DOXORUBICIN CARDIOTOXICITY3 Adriamycin and Related Anthracycline AntibioticsMolecular interactions between adriamycin and x-ray damage in mammalian tumor cellsCellular effects of combined adriamycin and x-irradiation in human tumor cellsAdriamycin cardiotoxicity in children.Case reports, literature review, and risk factorsRadiation-related myocardial injury.Management of Two CasesComplications of irradiation related to apparent drug potentiation by adriamycinAdriamycin and Enhanced Radiation Reaction in Normal Esophagus and SkinF. ANTHONY GRECO, M.D., HARMAR D. BRERETON, M.D., HARRY KENT, M.D., HARVEY ZIMBLER, M.D., JOHN MERRILL, M.D., RALPH E. JOHNSON, M.D.Cardiotoxicity of adriamycin and related anthracyclinesQuantification of combined radiation therapy and chemotherapy effects on critical normal tissuesUnusual cardiac reaction to chemotherapy following mediastinal irradiation in a patient with Hodgkin's diseaseCardiovascular Effects of Cancer TherapyScreening for Cardiovascular Disease in Survivors of Thoracic Radiation 1 January 1975Volume 82, Issue 1Page: 122-123KeywordsBody surface areaCardiomyopathiesHeart failureLungsRadiation therapySarcomaSkullSpine Issue Published: 1 January 1975 PDF DownloadLoading ...